Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Keeping HIV Patients on ART Will Have Long-Term Economic Benefits, Study Shows

October 6, 2011

Investments to keep 3.5 million people living with HIV on antiretroviral drugs provided by programs co-financed through the Global Fund to Fight AIDS, Tuberculosis and Malaria through 2020 will cost an estimated $14.2 billion, but "the financial savings would amount to between $12 billion and $34 billion," according to a study published in the journal PLoS One, Sarah Boseley reports in her "Global Health Blog" in the Guardian (10/5).

Researchers from the Results for Development Institute, Harvard School of Public Health, the Global Fund, and Imperial College in the U.K., used 2009 antiretroviral therapy (ART) prices and program costs to determine that such an "investment is expected to save 18.5 million life-years and return $12 to $34 billion through increased labor productivity, averted orphan care, and deferred medical treatment for opportunistic infections and end-of-life care," according to the study. The researchers note that the "estimates of ART program cost, particularly for service delivery and for orphan care, are limited by shortcomings in the available data" and did not examine the cost of scaling up existing ART programs, but do state that "[s]uch actions are likely to have favorable benefit-cost profiles" (Resch et al., 10/5).

Back to other news for October 2011


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
PEPFAR ART Cost Model Data Presented to PEPFAR Scientific Advisory Board
More Research on HIV Treatment in the Developing World

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement